BNIPL (BCL2 interacting protein like) is a bridge molecule linking apoptotic and cytoskeletal signaling pathways with context-dependent roles in cell fate determination. Mechanistically, BNIPL contains a BNIP-2 and Cdc42GAP homology (BCH) domain critical for interactions with Bcl-2 and Cdc42GAP 1, positioning it at the intersection of DNA fragmentation and morphological remodeling during apoptosis. BNIPL-1 suppresses hepatocellular carcinoma (HCC) cell growth by upregulating pro-apoptotic genes (p16INK4, IL-12, TRAIL) and downregulating proliferation-associated PTEN 2, while paradoxically, BNIPL-2 promotes HCC metastasis through Cdc42 activation and CD44 upregulation 3. In colorectal cancer, elevated BNIPL-2 correlates with poor prognosis and drives proliferation via CD44-mediated G2/M phase progression 4. Conversely, BNIPL is downregulated in laryngeal cancer, where overexpression suppresses proliferation, migration, and invasion 5. In glioblastoma, curcumin induces BNIPL expression as part of its pro-apoptotic mechanism 6. Clinically, BNIPL serves as a disease-specific biomarker: protective in laryngeal cancer and glioblastoma but oncogenic in HCC and colorectal cancer, suggesting context-dependent isoform or regulatory functions warranting further investigation.